260 related articles for article (PubMed ID: 34393077)
1. Resolution of One-Year Persisting COVID-19 Pneumonia and Development of Immune Thrombocytopenia in a Follicular Lymphoma Patient With Preceding Rituximab Maintenance Therapy: A follow-up Report and Literature Review of Cases With Prolonged Infections.
Yasuda H; Mori Y; Chiba A; Bai J; Murayama G; Matsushita Y; Miyake S; Komatsu N
Clin Lymphoma Myeloma Leuk; 2021 Oct; 21(10):e810-e816. PubMed ID: 34393077
[TBL] [Abstract][Full Text] [Related]
2. Prolonged COVID-19 in an Immunocompromised Patient Treated with Obinutuzumab and Bendamustine for Follicular Lymphoma.
Ueda Y; Asakura S; Wada S; Saito T; Yano T
Intern Med; 2022 Aug; 61(16):2523-2526. PubMed ID: 35650124
[TBL] [Abstract][Full Text] [Related]
3. Persistent COVID-19 Pneumonia and Failure to Develop Anti-SARS-CoV-2 Antibodies During Rituximab Maintenance Therapy for Follicular Lymphoma.
Yasuda H; Tsukune Y; Watanabe N; Sugimoto K; Uchimura A; Tateyama M; Miyashita Y; Ochi Y; Komatsu N
Clin Lymphoma Myeloma Leuk; 2020 Nov; 20(11):774-776. PubMed ID: 32933879
[No Abstract] [Full Text] [Related]
4. Persistent SARS-CoV-2 infection with multiple clinical relapses in two patients with follicular lymphoma treated with bendamustine and obinutuzumab or rituximab.
Franceschini E; Pellegrino M; Todisco V; Dolci G; Bettelli F; Meschiari M; Bedini A; Fregni-Serpini G; Grottola A; Guaraldi G; Pecorari M; Sarti M; Luppi M; Perno CF; Mussini C
Infection; 2023 Oct; 51(5):1577-1581. PubMed ID: 37076752
[TBL] [Abstract][Full Text] [Related]
5. Management of Persistent SARS-CoV-2 Infection in Patients with Follicular Lymphoma.
Martínez-Barranco P; García-Roa M; Trelles-Martínez R; Arribalzaga K; Velasco M; Guijarro C; Marcos J; Campelo C; Acedo-Sanz JM; Villalón L; Ricard P; García-Bueno MJ; Pérez-Fernández E; Rodríguez-Caravaca G; Peñalver FJ
Acta Haematol; 2022; 145(4):384-393. PubMed ID: 34839289
[TBL] [Abstract][Full Text] [Related]
6. Clearance of the SARS-CoV-2 Virus in an Immunocompromised Patient Mediated by Convalescent Plasma without B-Cell Recovery.
Basheer M; Saad E; Laskar O; Schuster O; Rechnitzer H; Zisman-Rozen S; Azoulay D; Assy N
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445605
[TBL] [Abstract][Full Text] [Related]
7. Prolonged SARS-CoV-2 Infection and Organizing Pneumonia in a Patient with Follicular Lymphoma, Treated with Obinutuzumab-Challenging Recognition and Treatment.
Łyżwa E; Sobiecka M; Lewandowska K; Siemion-Szcześniak I; Barańska I; Klatt M; Langfort R; Szturmowicz M; Tomkowski W
Viruses; 2023 Mar; 15(3):. PubMed ID: 36992402
[TBL] [Abstract][Full Text] [Related]
8. Prolonged shedding of infectious viruses with haplotype switches of SARS-CoV-2 in an immunocompromised patient.
Shoji K; Suzuki A; Okamoto M; Tsinda EK; Sugawara N; Sasaki M; Nogami Y; Kobayashi M; Oshitani H; Yanai M
J Infect Chemother; 2022 Jul; 28(7):1001-1004. PubMed ID: 35430092
[TBL] [Abstract][Full Text] [Related]
9. Prolonged viral positivity induced recurrent coronavirus disease 2019 (COVID-19) pneumonia in patients receiving anti-CD20 monoclonal antibody treatment: Case reports.
Deveci B; Saba R
Medicine (Baltimore); 2021 Dec; 100(52):e28470. PubMed ID: 34967391
[TBL] [Abstract][Full Text] [Related]
10. Overlap of immunotherapy-related pneumonitis and COVID-19 pneumonia: diagnostic and vaccine considerations.
Abid MB
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33931473
[TBL] [Abstract][Full Text] [Related]
11. A 63-Year-Old Woman with a History of Non-Hodgkin Lymphoma with Persistent SARS-CoV-2 Infection Who Was Seronegative and Treated with Convalescent Plasma.
Moore JL; Ganapathiraju PV; Kurtz CP; Wainscoat B
Am J Case Rep; 2020 Oct; 21():e927812. PubMed ID: 33009361
[TBL] [Abstract][Full Text] [Related]
12. Humoral and cellular responses after COVID-19 vaccination in anti-CD20-treated lymphoma patients.
Liebers N; Speer C; Benning L; Bruch PM; Kraemer I; Meissner J; Schnitzler P; Kräusslich HG; Dreger P; Mueller-Tidow C; Poschke I; Dietrich S
Blood; 2022 Jan; 139(1):142-147. PubMed ID: 34669919
[No Abstract] [Full Text] [Related]
13. Efficacy and Tolerability of a 2-Year Rituximab Maintenance Therapy in Patients with Advanced Follicular Lymphoma after Induction of Response with Rituximab-Containing First Line-Regimens (HUSOM Study).
Schneider T; Rosta A; Losonczy H; Radványi G; Ujj G; Egyed M; Illés Á; Jakucs J; Szerafin L; Gasztonyi Z; Masszi T; Iványi J; Demeter J; Dombi P; Tóth A; Borbényi Z
Pathol Oncol Res; 2018 Apr; 24(2):199-205. PubMed ID: 28432650
[TBL] [Abstract][Full Text] [Related]
14. Case Report: Effects of Anti-SARS-CoV-2 Convalescent Antibodies Obtained With Double Filtration Plasmapheresis.
Curtò D; Tomatis F; Gastoldi S; Galbusera M; Noris M; Raimondi F; Lorini FL; Falanga A; Marchetti M; Remuzzi G; Ruggenenti P
Front Immunol; 2021; 12():711915. PubMed ID: 34276706
[TBL] [Abstract][Full Text] [Related]
15. Migratory Pneumonia in Prolonged SARS-CoV-2 Infection in Patients Treated With B-cell Depletion Therapies for B-cell Lymphoma.
Lee J; Lee R; Beck KS; Han DH; Min GJ; Chang S; Jung JI; Lee DG
Korean J Radiol; 2023 Apr; 24(4):362-370. PubMed ID: 36907590
[TBL] [Abstract][Full Text] [Related]
16. Emergence of Multiple SARS-CoV-2 Antibody Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma Treatment.
Chen L; Zody MC; Di Germanio C; Martinelli R; Mediavilla JR; Cunningham MH; Composto K; Chow KF; Kordalewska M; Corvelo A; Oschwald DM; Fennessey S; Zetkulic M; Dar S; Kramer Y; Mathema B; Germer S; Stone M; Simmons G; Busch MP; Maniatis T; Perlin DS; Kreiswirth BN
mSphere; 2021 Aug; 6(4):e0048021. PubMed ID: 34431691
[TBL] [Abstract][Full Text] [Related]
17. Successful treatment of COVID-19 infection with convalescent plasma in B-cell-depleted patients may promote cellular immunity.
Kremer AE; Kremer AN; Willam C; Völkl S; Verhagen J; Achenbach S; van der Meijden ED; Lang V; Aigner M; Maier C; Tenbusch M; Korn K; Lutzny-Geier G; Spoerl S; Strauß R; Vetter M; Überla K; Neurath MF; Mackensen A; Schiffer M; Hackstein H
Eur J Immunol; 2021 Oct; 51(10):2478-2484. PubMed ID: 34350584
[TBL] [Abstract][Full Text] [Related]
18. SARS-CoV-2 infection in immunocompromised patients: humoral versus cell-mediated immunity.
Wei J; Zhao J; Han M; Meng F; Zhou J
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32727811
[TBL] [Abstract][Full Text] [Related]
19. Successful treatment of persisting SARS-CoV-2 infection in an immunocompromised patient with repeated nirmatrelvir/ritonavir courses: a case report.
Lindahl AL; Ahava MJ; Haukipää M; Kreivi HR; Lipponen A; Kortela E
Infect Dis (Lond); 2023 Aug; 55(8):585-589. PubMed ID: 37334428
[TBL] [Abstract][Full Text] [Related]
20. Rituximab maintenance improves overall survival of patients with follicular lymphoma-Individual patient data meta-analysis.
Vidal L; Gafter-Gvili A; Salles G; Bousseta S; Oberman B; Rubin C; van Oers MH; Fortpied C; Ghielmini M; Pettengell R; Witzens-Harig M; Dreger P; Vitolo U; Gomes da Silva M; Evangelista A; Li H; Freedman L; Habermann TM; Shpilberg O
Eur J Cancer; 2017 May; 76():216-225. PubMed ID: 28336303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
